Education
About Us
Working with TipRanks
Follow Us
Wockhardt Limited (IN:WOCKPHARMA)
:WOCKPHARMA
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,157.00 - ₹1,870.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹196.84B
Enterprise Value₹216.63B
Total Cash (Recent Filing)₹9.30B
Total Debt (Recent Filing)₹24.56B
Price to Earnings (P/E)100.2
Beta1.59
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.63
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio5.29
Price to Book (P/B)5.18
Price to Sales (P/S)7.42
P/FCF Ratio-85.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving LeverageA materially lower debt-to-equity ratio (0.46 vs 0.70) and a 53.51% equity ratio improve financial flexibility and reduce interest burden. This durable improvement in capital structure supports refinancing capacity and investment without immediate reliance on earnings recovery.
Revenue Growth And Gross Margin RecoverySustained revenue growth with a noticeable rise in gross margin signals operational improvements—better pricing, mix or manufacturing efficiency. If maintained, higher gross margin provides a structural pathway to restore operating leverage and eventually translate revenue into positive profits.
Diversified Pharma Business ModelExposure to formulations, APIs, exports and contract/commercialization creates multiple revenue channels. This product and geographic diversification cushions against single-market shocks, supports cross-selling and capacity utilization, and is a durable foundation for cash generation when operations normalize.
Bears Say
Persistent Net LossesOngoing net losses erode retained earnings and restrict the company's ability to self-fund R&D, capex and working capital needs. Over months this reduces strategic optionality, pressures stakeholder confidence and increases dependence on external financing to sustain operations.
Negative Operating And Free Cash FlowNegative operating and free cash flow are structural constraints on reinvestment and debt servicing. Without predictable cash generation, the firm faces continued liquidity stress, higher refinancing risk, and limited ability to convert margin improvements into durable balance sheet repair.
Eroding Equity And Weak Profitability MetricsDeclining shareholders' equity and a negative ROE indicate the company has not generated adequate returns for shareholders. Coupled with weak EBIT/EBITDA margins, this suggests structural profitability issues that could prolong recovery and limit capacity to attract long-term capital.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1157.00 and its highest was ₹1870.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹196.84B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Jun 03, 2026 which is in 78 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on Feb 10, 2026. The company reported ₹3.631 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.631.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹3.631 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.086%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―